WO2000051585A3 - Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume - Google Patents

Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume Download PDF

Info

Publication number
WO2000051585A3
WO2000051585A3 PCT/US2000/005196 US0005196W WO0051585A3 WO 2000051585 A3 WO2000051585 A3 WO 2000051585A3 US 0005196 W US0005196 W US 0005196W WO 0051585 A3 WO0051585 A3 WO 0051585A3
Authority
WO
WIPO (PCT)
Prior art keywords
naturally
occurring
bone volume
increasing bone
selective agonist
Prior art date
Application number
PCT/US2000/005196
Other languages
French (fr)
Other versions
WO2000051585A2 (en
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble, James Richard Hartke, Mark Walden Lundy, Mitchell Anthony Delong filed Critical Procter & Gamble
Priority to JP2000602053A priority Critical patent/JP2002538105A/en
Priority to IL14512800A priority patent/IL145128A0/en
Priority to CA002366755A priority patent/CA2366755A1/en
Priority to EP00915937A priority patent/EP1158969A2/en
Priority to AU37119/00A priority patent/AU3711900A/en
Publication of WO2000051585A2 publication Critical patent/WO2000051585A2/en
Publication of WO2000051585A3 publication Critical patent/WO2000051585A3/en
Priority to NO20014192A priority patent/NO20014192L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

The present invention relates to novel methods of increasing bone volume comprising the administration of a non-naturally-occurring selective EP1 agonist to a subject in need of such treatment. This invention further relates to a method of treating or preventing bone disorders comprising the administration of a non-naturally-occurring selective EP1 agonist to a subject in need of such treatment.
PCT/US2000/005196 1999-03-05 2000-03-01 Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume WO2000051585A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000602053A JP2002538105A (en) 1999-03-05 2000-03-01 Use of a non-naturally occurring EP1 selective agonist for increasing bone volume
IL14512800A IL145128A0 (en) 1999-03-05 2000-03-01 Method of increasing bone volume using non-naturally-occurring ep1 selective agonists
CA002366755A CA2366755A1 (en) 1999-03-05 2000-03-01 Method of increasing bone volume using non-naturally-occurring ep, selective agonists
EP00915937A EP1158969A2 (en) 1999-03-05 2000-03-01 Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
AU37119/00A AU3711900A (en) 1999-03-05 2000-03-01 Method of increasing bone volume using non-naturally-occurring ep1 selective agonists
NO20014192A NO20014192L (en) 1999-03-05 2001-08-29 Method of increasing bone volume using non-naturally occurring EP1 selective agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12306399P 1999-03-05 1999-03-05
US60/123,063 1999-03-05

Publications (2)

Publication Number Publication Date
WO2000051585A2 WO2000051585A2 (en) 2000-09-08
WO2000051585A3 true WO2000051585A3 (en) 2001-01-25

Family

ID=22406507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005196 WO2000051585A2 (en) 1999-03-05 2000-03-01 Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume

Country Status (10)

Country Link
EP (1) EP1158969A2 (en)
JP (1) JP2002538105A (en)
AU (1) AU3711900A (en)
CA (1) CA2366755A1 (en)
CO (1) CO5150205A1 (en)
IL (1) IL145128A0 (en)
NO (1) NO20014192L (en)
NZ (1) NZ513828A (en)
PE (1) PE20001552A1 (en)
WO (1) WO2000051585A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006118173A1 (en) 2005-04-28 2008-12-18 小野薬品工業株式会社 Transdermal absorption preparation
KR20090075864A (en) 2006-10-26 2009-07-09 오노 야꾸힝 고교 가부시키가이샤 Adhesive preparation
JPWO2009133863A1 (en) 2008-04-28 2011-09-01 国立大学法人浜松医科大学 Immunopotentiator comprising EP1 agonist
EP2542263A4 (en) * 2010-03-05 2013-07-31 Univ Rochester Ep1 inhibition

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
WO1992021350A1 (en) * 1991-05-29 1992-12-10 Sepracor, Inc. Combination of nsaids and prostaglandins and uses therefor
WO1999012551A1 (en) * 1997-09-09 1999-03-18 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring fp selective agonists
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
WO2000051616A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
WO1992021350A1 (en) * 1991-05-29 1992-12-10 Sepracor, Inc. Combination of nsaids and prostaglandins and uses therefor
WO1999012551A1 (en) * 1997-09-09 1999-03-18 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring fp selective agonists
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
WO2000051616A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MILEY, C. ET AL: "Activity and receptor selectivity of 17 - phenyl - trinor PGE2, 9- methylene -9- deoxy - PGE2 and 9-substituted analogs at cloned human EP1 and EP3 receptors.", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, (1998) VOL. 215, NO. 1-2, PP. MEDI 50B. MEETING INFO.: 215TH AMERICAN CHEMICAL SOCIETY NATIONAL MEETING DALLAS, TEXAS, USA MARCH 29-APRIL 2, 1998 AMERICAN CHEMICAL SOCIETY., XP000952036 *
SUDA M ET AL: "Prostaglandin E receptor subtypes in mouse osteoblastic cell line.", ENDOCRINOLOGY, (1996 MAY) 137 (5) 1698-705., XP000952014 *
WEINREB M ET AL: "The anabolic effect of PGE2 in rat bone marrow cultures is mediated via the EP4 receptor subtype.", AMERICAN JOURNAL OF PHYSIOLOGY, (1999 FEB) 276 (2 PT 1) E376-83., XP000952048 *
WOODIEL, FLORENCE N. ET AL: "Anabolic effects of prostaglandins in cultured fetal rat calvariae: Structure-activity relations and signal transduction pathway", J. BONE MINER. RES. (1996), 11(9), 1249-1255, XP000952077 *

Also Published As

Publication number Publication date
NZ513828A (en) 2001-09-28
EP1158969A2 (en) 2001-12-05
JP2002538105A (en) 2002-11-12
IL145128A0 (en) 2002-06-30
WO2000051585A2 (en) 2000-09-08
AU3711900A (en) 2000-09-21
NO20014192D0 (en) 2001-08-29
CO5150205A1 (en) 2002-04-29
PE20001552A1 (en) 2001-01-30
CA2366755A1 (en) 2000-09-08
NO20014192L (en) 2001-11-05

Similar Documents

Publication Publication Date Title
EP1583821A4 (en) Methods and compositions for treating urological disorders using 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 76
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
AU2604301A (en) Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
AU2002367397A1 (en) Method and apparatus for improved vascular related treatment
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
HK1064261A1 (en) Method for the treatment of tobacco.
AU2001268422A1 (en) Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
AU2001285747A1 (en) Method for the treatment of tobacco
ZA200309733B (en) Method and apparatus for distributing treatment agents.
AU2002367023A1 (en) Compositions and methods for treating heart failure
AU2001271887A1 (en) Methods for diagnosis and treatment of psychiatric disorders
AU2002365057A1 (en) Compositions and methods for treating heart failure
AU2002245204A1 (en) Methods for treating blood coagulation disorders
AU2003215190A1 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
WO2000051585A3 (en) Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
MXPA03004017A (en) Method for the treatment of inflammation.
IL162053A0 (en) Method for the treatment of bone disorders
ZA200210361B (en) Method of administering bishosphonates.
AU2003210554A1 (en) Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
WO2001000191A3 (en) Use of fosphenytion for the treatment of acute neuropathic pain
AU5169200A (en) Methods and compositions for treating breakthrough pain
ZA991786B (en) Therapeutic treatment for asthma.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 145128

Country of ref document: IL

Ref document number: IN/PCT/2001/00765/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 513828

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09914529

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2366755

Country of ref document: CA

Ref document number: 2366755

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 602053

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 37119/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000915937

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000915937

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000915937

Country of ref document: EP